AAX Biotech is a research-driven company focused on enabling and accelerating the development of highly effective antibody-based medicines. By offering innovative solutions to well-recognized challenges in the rapidly expanding biotherapeutics market, AAX strive to accelerate drug development and improve therapeutic outcomes.
We are happy to introduce LSI Epsilons 9th investment Abarceo Pharma AB, a pre-clinical stage company, developing a platform for the treatment of mitochondrial diseases, with an initial focus on Type 2 Diabetes (T2D).We look forward to work closely with Adam Bruce,...
So excited to introduce our 8th investment. SampleFacts is reinventing blood 🩸 sampling by separating blood and plasma instantly. We look forward to work closely with Maryam Poorafshar, Kristina Svensson, Frida Ekholm, Ulf Landegren, Jon-Sverre Schanche and rest of...
Glad to introduce our seventh investment Bioservo AB. Bioservo is a world-leading company within wearable grip-strengthening systems. Looking forward to work with Petter Bäckgren, Mikael Wester, Philip Simonson, Annika Rydgård and rest of the team. Listen to Petter...